Pyxis Oncology, Inc. (PYXS)
1.87
+0.19
(+11.31%)
USD |
NASDAQ |
Nov 20, 12:26
Pyxis Oncology Cash from Investing (Quarterly) : -37.29M for Sept. 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -37.29M |
| June 30, 2026 | 21.30M |
| March 31, 2026 | 16.37M |
| December 31, 2025 | 16.26M |
| September 30, 2025 | 11.47M |
| June 30, 2025 | 15.30M |
| March 31, 2025 | 15.82M |
| December 31, 2024 | 26.66M |
| September 30, 2024 | -0.008M |
| June 30, 2024 | 0.004M |
| March 31, 2024 | -18.50M |
| December 31, 2023 | 10.23M |
| Date | Value |
|---|---|
| September 30, 2023 | 6.571M |
| June 30, 2023 | -22.26M |
| March 31, 2023 | -99.39M |
| December 31, 2022 | -1.858M |
| September 30, 2022 | -4.266M |
| June 30, 2022 | -0.129M |
| March 31, 2022 | -0.146M |
| December 31, 2021 | 0.00 |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 0.00 |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Cypherpunk Technologies, Inc. | -6.00M |
| Cue Biopharma, Inc. | 0.00 |
| Yarrow Bioscience, Inc. | -5.00M |
| Faeth Therapeutics, Inc. | 0.175M |
| Indaptus Therapeutics, Inc. | 0.0882M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -16.29M |
| Cash from Financing (Quarterly) | 38.58M |
| Free Cash Flow | -70.93M |
| Free Cash Flow Per Share (Quarterly) | -0.1951 |
| Free Cash Flow to Equity (Quarterly) | -15.86M |
| Free Cash Flow to Firm (Quarterly) | -16.29M |
| Free Cash Flow Yield | -45.42% |